Resting-state Functional Connectivity of the Raphe Nuclei in Major Depressive Disorder: A Multi-site Study.
Yajuan Zhang,Chu-Chung Huang,Jiajia Zhao,Yuchen Liu,Mingrui Xia,Xiaoqin Wang,Dongtao Wei,Yuan Chen,Bangshan Liu,Yanting Zheng,Yankun Wu,Taolin Chen,Yuqi Cheng,Xiufeng Xu,Qiyong Gong,Tianmei Si,Shijun Qiu,Jingliang Cheng,Yanqing Tang,Fei Wang,Jiang Qiu,Peng Xie,Lingjiang Li,Yong He,Ching-Po Lin,Chun-Yi Zac Lo
DOI: https://doi.org/10.1016/j.nicl.2023.103359
IF: 4.891
2023-01-01
NeuroImage Clinical
Abstract:Accumulating evidence showed that major depressive disorder (MDD) is characterized by a dysfunction of serotonin neurotransmission. Raphe nuclei are the sources of most serotonergic neurons that project throughout the brain. Incorporating measurements of activity within the raphe nuclei into the analysis of connectivity characteristics may contribute to understanding how neurotransmitter synthesized centers are involved in thepathogenesisof MDD. Here, we analyzed the resting-state functional magnetic resonance imaging (RS-fMRI) dataset from 1,148 MDD patients and 1,079 healthy individuals recruited across nine centers. A seed-based analysis with the dorsal raphe and median raphe nuclei was performed to explore the functional connectivity (FC) alterations. Compared to controls, for dorsal raphe, the significantly decreased FC linking with the right precuneus and median cingulate cortex were found; for median raphe, the increased FC linking with right superior cerebellum (lobules V/VI) was found in MDD patients. In further exploratory analyzes, MDD-related connectivity alterations in dorsal and median raphe nuclei in different clinical factors remained highly similar to the main findings, indicating these abnormal connectivities are a disease-related alteration. Our study highlights a functional dysconnection pattern of raphe nuclei in MDD with multi-site big data. These findings help improve our understanding of the pathophysiology of depression and provide evidence of the theoretical foundation for the development of novel pharmacotherapies.